Document is current
Any future updates will be listed below
-
Authors
Slowley, Alexander
d’Estrubé, Tim
Neukirch, Konstantin
Kienzle, Scarlette
Junker, Sophia
Zhang, Shiyuan
Wilke, Thomas
Göthert, Joachim R.
-
Funding
Funding for this research was provided by:
GSK
- License Information
-
More Information
Article History
Received: 22 December 2025
Accepted: 20 April 2026
First Online: 4 June 2026
Declarations
:
: Not applicable.
: Alexander Slowley was employed by GSK at the time of study conduct, holds financial equities in GSK, and is currently employed by Vertex Pharmaceuticals, London, UK. Tim d’Estrubé is employed by GSK and holds financial equities in GSK. Konstantin Neukirch is employed by GSK and holds financial equities in GSK. Scarlette Kienzle is employed by Ingress-Health HWM GmbH, a Cytel company. Sophia Junker was employed by Ingress-Health HWM GmbH, a Cytel company, at the time of study conduct. Shiyuan Zhang is employed by GSK and holds financial equities in GSK. Thomas Wilke is employed by the University of Wismar and worked as a consultant for Cytel at the time of study conduct. Joachim R. Göthert received payments and honoraria from GSK, Novartis, BMS, pharma & AOP Orphan Pharmaceuticals and participated on advisory boards for GSK, Novartis, BMS and AOP Orphan Pharmaceuticals.
